Hyundai Pharmaceutical Co., Ltd.

Total Valuation

Hyundai Pharmaceutical Co., Ltd. carries a market capitalization of 118.39B, placing it among publicly traded companies globally. Its enterprise value stands at 342.72B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Hyundai Pharmaceutical Co., Ltd. currently has 26.14M shares outstanding.

Valuation Ratios

Hyundai Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 189.42. The price-to-sales ratio is 2.17, and the price-to-book ratio stands at 4.47.

Enterprise Valuation

On an enterprise value basis, Hyundai Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 94.11 and an EV/FCF ratio of 63.31. The EV/Sales ratio of 2.39 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 94.11 provides insight into valuation relative to core operating earnings.

Financial Position

Hyundai Pharmaceutical Co., Ltd. maintains a current ratio of 1.28, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 37.18, indicating elevated leverage, while an interest coverage ratio of 3.96 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Hyundai Pharmaceutical Co., Ltd. posts a return on equity of 2.42 and a return on invested capital of 1.42.

Taxes

Over the trailing twelve months, Hyundai Pharmaceutical Co., Ltd. has paid 995.36M in income taxes, reflecting an effective tax rate of 37.70.

Stock Price Statistics

Hyundai Pharmaceutical Co., Ltd.'s stock has gained approximately 30.35971% over the past 52 weeks. The 50-day moving average sits at 7,119.10, while the 200-day moving average is 7,491.60.

Income Statement

Over the trailing twelve months, Hyundai Pharmaceutical Co., Ltd. generated 143.59B in revenue and converted that into 1.64B in net income, yielding earnings per share of 62.93. EBITDA reached 3.64B, while operating income came in at 3.64B.

Balance Sheet

Hyundai Pharmaceutical Co., Ltd. holds 18.94B in cash and equivalents against 50.12B in total debt, resulting in a net debt position of 31.14B. Total book value stands at 69.70B, with working capital of 21.74B providing operational flexibility.

Cash Flow

Hyundai Pharmaceutical Co., Ltd. produced -977.71M in operating cash flow over the past twelve months. After subtracting -5.82B in capital expenditures, free cash flow totaled -6.80B - equivalent to -260.01 per share.

Margins

Hyundai Pharmaceutical Co., Ltd. operates with a gross margin of 42.13, reflecting its pricing power and cost economics. The operating margin of 2.54 and net profit margin of 1.15 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Hyundai Pharmaceutical Co., Ltd.'s most recent stock split took place on October 20, 2017 with a 500:513 split ratio.

Scores

Hyundai Pharmaceutical Co., Ltd. posts an Altman Z-Score of 3.28, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.